Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.

Slides:

Advertisements

Similar presentations

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.

Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section

By Gracie Canales August 10, 2010

Molecular testing for detection of Mycobacterium tuberculosis San Francisco Department of Public Health Laboratory.

Dr. Thaweesak Tirawatnapong Chula Medical Research Center (Chula MRC)

Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.

` COMPARATIVE ACCURACY OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST AND SPUTUM MICROSCOPY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN HIV POSITIVE.

GeneXpert for Detection of MTB and Rifampin Resistance

New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.

THE YIELD OF GENEXPERT IN PULMONARY TUBERCULOSIS&RIFAMPICIN RESISTANCE

Ruqaya Mustafa Ali Genetic Engineering and Biotechnology.

Improving diagnosis TB laboratory strengthening.

Country Update: Tuberculosis in Thailand

Dr R Ramachandran 5 th Joint International Monitoring Mission to Review NTP Thailand 5th JMM Thailand.

1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.

Implementation of Diagnostics in Resource-Limited Settings Amy Piatek Global Health Bureau, Office of Health, Infectious Diseases & Nutrition U.S. Agency.

Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.

World Health Organization TB Case Definitions

Standards for Laboratory Diagnosis of Tuberculosis Professor Brian I. Duerden Inspector of Microbiology and Infection Control, Department of Health.

Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG.

Access to TB Drugs and Diagnostics Gregg Gonsalves Open Society Foundations Division of the Epidemiology of Microbial Diseases, Yale School of Public Health.

Module 11: Clinical guide to Xpert MTB/RIF Global Laboratory Initiative – Xpert MTB/RIF Training Package.

TB Diagnostics: Update on Policies and Pipeline

Early and Improved TB case detection through the use of GeneXpert technology in Nepal.

COMPREHENSIVE APPROACH TO TB DIAGNOSIS

Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.

Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.

Xpert in the diagnostic algorithm of pulmonary TB in adult patients who are neither high risk for HIV, nor high risk for MDR-TB Preparations for the global.

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director

PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,

LABORATORIES and DIAGNOSIS of TUBERCULOSIS Assoc. Prof. Alpaslan Alp Hacettepe University Faculty of Medicine Department of Medical Microbiology.

British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.

Tuberculosis Research of INA-RESPOND on Drug-resistant

Volatronic Marketing plan draft.

Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.

Implementation of Thin Layer Agar for Mycobacterium culture in rural Kenya Médecins Sans Frontières.

1 |1 | Dr Karin Weyer Stop TB Department Geneva, Switzerland Strategic guidance on the use of laboratory technologies DEWG Meeting, Geneva: 13 October.

PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.

Revision of new diagnostics for TB

PMDT expansion is first of all expansion of DR-TB detection services Workshop on the development and implementation of supervision and patient support.

High cost of Xpert MTB/RIF ® testing per tuberculosis case diagnosed at Partners in Hope Medical Center, a public private HIV care clinic in Lilongwe,

Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-

NAAT Is it Time for a New Option in California?. Background CDC 2009 guidelines recommend NAAT for each patient with suspected TB for whom the test result.

Go to View > Master > Slide Master to edit Place, Month Year GLI and Global Fund focal point Feedback and updates Rachel Bauquerez.

Challenge of Diagnosing Smear-Negative TB Department of Infectious Diseases.

TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.

Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.

Do we need to test for isoniazid resistance? No conflict of interest Claudia Denkinger, MD PhD McGill University, Montreal Foundation for Innovative New.

Early TB case detection in pre-trial detention centers (SIZOs) and prison colonies in Ukraine 46 th Union World Conference on Lung Health Cape Town, South.

Revolutionizing TB Control with Innovation in New Diagnostics Dr Giorgio Roscigno Chief Executive Officer, FIND Reversing the Tide: the End of Tuberculosis,

LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.

The Factor II (Prothrombin) G20210A Detection and Genotyping

Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.

Roundtable. Detection and treatment of TB Andrew Black.

Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.

TB – LABORATORY INVESTIGATIONS by Dr. Zubaidah Abdul Wahab Datin Dr. Ganeswrie Raj 1.

Article review Rapid Molecular Detection of Tuberculosis and Rifampin Resistance [MTB-RIF test] Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann,

New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.

CASES OF PLEURAL EFFUSION (n=56)

TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.

LAM assay: overview and practical guidance on its adoption and use

Integrated Testing on the GeneXpert

Novel approaches to TB infection control in private general hospitals in Georgia T Gabunia1, I Khonelidze, N Solomonia, T Merabishvili, M Makharadze,

Division of Infectious Diseases

DR-TB Case-finding and Referral Procedures

Deciphering TB Lab Reports

TB Screening and Differentiated Service Delivery: State of the Art

Decade of field experience with TB GeneXpert IAS 2019 Satellite session Mexico, 22 July 2019 By Jean de Dieu IRAGENA Technical Officer Laboratory WHO/AFRO,

Presentation transcript:

Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference Laboratory, National Centre Tuberculosis and Lung Disease, Tbilisi, Georgia

Global Consultation on the implementation of Xpert MTB/RIF System for rapid daignosis of TB and MDR-TB 30 Nov-2 Dec 2010 (Geneva, Switzerland) Meeting objectives Diagnostic algorithms for risk groups 2. Programmatic implementation: tiered lab services 3. Pricing considerations and market dynamics 4. Cost-effectiveness and cost-benefit considerations 5. Global framework for rapid uptake in countries WHO Policy announcement: 7 Dec 2010

WHO recommendations 2006-2010 2007 Comercial liquid culture/DST Rapid speciation (MPT64) 2008 Line probe assay (Rif&INH) 2009 LED-based FM Non-commercial culture (MODS, CRI, NRA) 2010 - Catrige-based Automated NAAT(Xpert MTB/RIF)

To face the burden of TB, TB/HIV and especially MDRTB, we need a rapid test for TB and drug susceptibility The detection of RIF resistance may be a good surrogate marker for MDR-TB, as an estimated 90% or RIF-resistant TB is also resistant to INH In the past 4 years, WHO has worked intensively with FIND, UNITAID, USAID and other partners to pursue new TB diagnostics and rapid uptake at country level

Xpert MTB/RIF assay & GeneXpert instrument The rapid test: Detects M. tuberculosis and RIF resistance by PCR amplification Process is hemi nested and the amplified target is detected in real time by six color fluorescent molecular beacons

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument The new DNA test for TB is a fully automated diagnostic molecular test that uses modern technology: Extraction and purification DNA/RNA & Amplification Multiplex detection (automated)

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument

Xpert MTB/RIF assay & GeneXpert instrument Time to results - 100 minutes Throughput - Total hands-on time of 2 min, total daily throughput depends on the size of instrument (4 cartridges system – up to 16 tests) Specimen type – Sputum, may work with other simples except for venous blood Sample preparation – Two steps Biosafety level - Level 1 Readout – Simple and color coded, readout on a computer Waste disposal – Plastic reagents tubes can recycled, cartridges can be incinerated

Xpert MTB/RIF assay & GeneXpert instrument Closed system – no contamination risk Controls – Positive control included in test kit Reagents – All reagents in self-contains kit, kit contains a pipette to transfer liquid sputum from container to cartridge Storage/stability (including reagents) – Maximum shelf-life of 14 months Reagents stable at temperature 2-280 Instrumentations – Requires annual maintenance Power requirement – Low power requirement compared with other PCR system Training – Approximately 1 day of training required

Xpert MTB/RIF assay & GeneXpert instrument Sensitivity and specificity Compared culture Sensitivity for AFB+/culture+ 98.2% Sensitivity for AFB-/culture+ 72.5% Specificity 99.2% Rifampicin resistance detection Sensitivity – 98% Specificity – 99%

Xpert MTB/RIF assay & GeneXpert instrument Projected prices reductions based on increases in the number of tests Year 2011 2012 2014 Number of tests (million) 0.6m 1.7m 3.7m Price per Test $16.86 $14.00 $10.72 Average Price Reduction 75% 79% 84%

RECOMMENDATIONS • In high MDR-TB settings: Persons at risk of MDR-TB (treatment failures, other retreatment cases, close contacts of MDR-TB cases) should be tested using Xpert MTB/RIF as the primary diagnostic test; Strong recommendation • In high HIV prevalence settings: Persons living with HIV who have signs and symptoms of TB, those seriously ill and suspected of having TB regardless of HIV status, and those with unknown HIV status presenting with strong clinical evidence of HIV infection, should be tested using Xpert MTB/RIF as the primary diagnostic test; Strong recommendation In other settings: Xpert MTB/RIF is recommended as the primary diagnostic test where available, including in persons living with HIV in these settings, or as a follow-on test (at higher level of the health service) after screening by sputum smear microscopy (at lower level of the health service) or after screening by chest radiology; Conditional recommendation

• Access to conventional microscopy, culture and DST is still needed • Recommendations apply to the use of Xpert MTB/RIF in sputum specimens • Recommendations support the use of one sputum specimen

Thank you for your attention